Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist. It is described in research as an incretin mimetic carrying structural modifications that extend its half-life. Research examines its role in glucose-dependent insulin signaling, gastric emptying, and the central pathways that register satiety. Published reviews trace its discovery and development alongside liraglutide, an earlier compound in the same class, and a semaglutide product has been described as a weight loss drug for chronic weight management.

Semaglutide acts at the GLP-1 receptor. Research describes its effect on insulin release as glucose-dependent rather than unconditional stimulation. It has also been explored for slowing the rate at which the stomach empties, which is associated with prolonged fullness. Rodent work reports that semaglutide lowers body weight through distributed neural pathways, supporting the view that it acts on both peripheral glucose handling and central appetite signaling.

Research has studied semaglutide for weight loss in people with obesity without diabetes, including a systematic review and meta-analysis and long-term analyses from the SELECT randomized controlled trial. Other work has examined its clinical pharmacokinetics, its effect on lean mass, the neural pathways involved in body weight reduction in rodents, and outcomes in heart failure with preserved ejection fraction in an observational comparison with tirzepatide.

Safety of semaglutide has been summarized in a dedicated published review. A study in JAMA Ophthalmology examined the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide, and a systematic review assessed its effect on lean mass during clinical trials. Slowed gastric emptying is part of its studied mechanism. Detailed adverse event rates are not summarized here, and the primary literature should be consulted for specifics.

Research protocols have used 250 to 2,000 mcg per administration, given once weekly in the morning in a fasted state, stepping up from 250 mcg to 2 mg by week 13. The reported cycle is continuous until target weight loss, with a subcutaneous route described. This information reflects research protocols only and is not a recommendation. Each CoreX order ships with a protocol guide for laboratory reference.